Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CLL1/anti-CD33 CAR-T cells LCAR-AMDR

A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigens (TAAs) C-type-lectin-like molecule-1 (CLL-1; CLL1; C-type lectin domain family 12 member A; CLEC12A) and CD33, with potential immunomodulating and antineoplastic activities. Upon administration, the anti-CLL1/anti-CD33 CAR-T cells LCAR-AMDR specifically and simultaneously target and bind to CD33- and CLL1-expressing tumor cells. This induces selective toxicity in CD33- and CLL1-expressing tumor cells. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and is overexpressed on myeloid leukemia cells. CLL1, a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, is overexpressed in leukemic stem cells (LSCs) and plays an important role in disease progression and relapse for myeloid malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CLL1/CD33 CAR T cells LCAR-AMDR
CLL-1/CD33-targeted CAR T cells LCAR-AMDR
LCAR-AMDR
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search